CBT
ALLO icon

Capital Bank & Trust’s Allogene Therapeutics ALLO Stock Holding History

Capital Bank & Trust’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-116,948
Closed -$3.05M – 16
2021
Q2 		$3.05M Sell
116,948
-3,508
-3% -$100K 0.04% 157
2021
Q1 		$4.25M Sell
120,456
-3,206
-3% -$108K 0.05% 162
2020
Q4 		$3.12M Sell
123,662
-19,327
-14% -$630K 0.04% 167
2020
Q3 		$5.39M Buy
142,989
+3,949
+3% +$149K 0.07% 134
2020
Q2 		$5.95M Buy
+139,040
New +$5.03M 0.09% 128

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital Bank & Trust's ALLO Position: Q3 2021 in Review

Capital Bank & Trust sold out of Allogene Therapeutics (ALLO) in Q3 2021, closing a stake of 116,948 shares — an estimated $3.05M sold.

Capital Bank & Trust first reported a position in ALLO in Q2 2020 and held it in 5 quarters. The position peaked at $5.95M in Q2 2020. 169 funds tracked by Wall St. Rank hold ALLO as of Q3 2021.

  • Capital Bank & Trust reported no remaining Allogene Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Capital Bank & Trust sold 116,948 Allogene Therapeutics shares in Q3 2021, an estimated $3.05M.
  • Capital Bank & Trust first reported a position in Allogene Therapeutics in Q2 2020 and held it in 5 quarters.
  • Capital Bank & Trust's Allogene Therapeutics position peaked at $5.95M in Q2 2020.
  • 169 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2021.

Based on Capital Bank & Trust's 13F filing for Q3 2021, filed 15 Nov 2021.